When we detect a group of jointly administered cases, we mark the associated and lead cases. -4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year Financial Guidance- MISSISSAUGA, Ontario , March 13, 2018 /PRNewswire/ -- Aralez Pharmaceuticals

The Debtors’ chapter 11 cases are jointly administered for procedural purposes only under Aralez Pharmaceuticals US Inc., No. Aralez Pharmaceuticals R&D Inc. 18-12426

27]. Aralez Pharmaceuticals (NASDAQ:ARLZ-OLD) plummets 76% premarket on increased volume after announcing that it has filed for Chapter 11 bankruptcy and …
Data Provided by Refinitiv. Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular and other specialty areas. August 10, 2018 MISSISSAUGA, Ontario , June 29, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc.  (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2018 annual meeting (the "Meeting") of the shareholders of the Company (the "Shareholders")

-Focus on Canadian Operations, supported by Toprol-XL® Franchise Revenues and Vimovo® Royalties- -Discontinuation of U.S. Commercial Operations, with Significant Reductions in Operating Expenses- -Actively Exploring Strategic Alternatives for Business- MISSISSAUGA, Ontario , May 8, 2018 August 10, 2018 All rights reserved. MISSISSAUGA, ON, Nov. 29, 2018 /CNW/ - Aralez Pharmaceuticals Inc. (" Aralez " or the " Company ") announced today that it and certain of its affiliates will seek court approval for the sale of its VIMOVO ®  royalties and Canadian operations to Nuvo Pharmaceuticals Inc. Aralez Pharmaceuticals US Inc.

Petition Chapter 11 Voluntary Petition for Non-Individual. Aralez Pharmaceuticals Holdings Limited On May 17, 2019, the Effective Date of the Plan occurred, and the Plan was consummated.The Bankruptcy Court has set the following deadlines for filing proofs of claim against the Debtors:Click on "Submit a Claim" above to download a proof of claim form and for more information regarding filing a claim against the Debtors.A hearing on the Debtors' First Day Motions was held on August 13, 2018 at 11:00 a.m. (ET) before the Honorable Martin Glenn, United States Bankruptcy Court for the Southern District of New York, One Bowling Green, Courtroom 523, New York, New York 10004. August 10, 2018 The combination of POZEN Inc. and Tribute Pharmaceuticals represents an important strategic transformation, creating Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform. Minimum 15 minutes delayed. The combination of POZEN and Tribute Pharmaceuticals represents an important strategic transformation that created Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform. August 10, 2018 18-12428 On March 8, 2019, the Bankruptcy Court entered an order approving the Disclosure Statement.
Court File No. Order for Relief Entered. Transactions to be valued at an aggregate of U.S. $250 million Commences Voluntary Proceedings under CCAA in Canada and Chapter 11 in the United States Company to Continue Operating Business and Serving Customers As Usual MISSISSAUGA, Ontario , Aug. 10, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. Commences Voluntary Proceedings under CCAA in Canada and Chapter 11 in the United States. Aralez Pharmaceuticals Trading Designated Activity Company

Our primary product is an a$$-kicking email briefing sent to Members every Sunday. Petition Chapter 11 Voluntary Petition for Non-Individual. 1985, c. C-36, AS AMENDED AND IN THE MATTER OF A … 18-12429

18-12427 -1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced financial results for the first quarter ending March 31, 2018 . Transactions valued at an aggregate of U.S. $240 million. Just kidding. © 2020 Aralez Pharmaceuticals Inc. Aralez Pharmaceuticals US Inc. CURATED DISRUPTION NEWS . Cases covers new Chapter 11, Chapter 15, bankruptcy filings and restructurings. Join below today.